



October 9, 2026

Company Name: HOYA CORPORATION
Representative: Eiichiro Ikeda, President and CEO
(Code: 7741, TSE Prime Market)
Contact: Corporate Communication Department
Telephone: +81-(0)3-6911-4824

Notice Regarding the Transfer of Shares of MID Labs

HOYA Corporation has decided to transfer all shares it holds in Medical Instrument Development Laboratories, Inc. ("MID Labs"), a subsidiary of HOYA, and entered into a definitive agreement today. Accordingly, HOYA hereby announces the transaction as follows.

1. Purpose of the Share Transfer

MID Labs, a consolidated subsidiary of HOYA Corporation, has been engaged in the manufacture and sale of vitreoretinal surgical instruments. The HOYA Group continuously reviews its business portfolio in response to changes in the external and business environments with the aim of enhancing corporate value. After comprehensively considering the optimal allocation of management resources across the Group and its future growth strategy, HOYA has decided to transfer all shares of MID Labs to Bausch + Lomb Corporation.

2. Overview of the Subsidiary to Be Transferred

Overview of the Subsidiary to Be Transferred

(1) Name	Medical Instrument Development Laboratories, Inc. (MID Labs)		
(2) Address	557 McCormick Street, San Leandro, CA 94577, USA		
(3) Representative	Kai Chen, CEO		
(4) Year Founded	1981		
(5) Principal Business	Manufacture and sale of vitreoretinal surgical instruments		
(6) Capital Stock	USD 146 million		
(7) Major Shareholder and Ownership Ratio	HOYA Corporation: 100%		
(8) Relationship with HOYA Corporation	Capital relationship	MID Labs is a consolidated subsidiary of HOYA Corporation.	
	Personnel relationship	We have appointed a director to the company.	
	Business relationship	There are purchase and sales transactions between the company and HOYA Corporation.	
(9) Financial Position and Operating Results for the Past Three Fiscal Years (USD millions)			
Fiscal year ended	March 2026	March 2025	March 2024
Total equity	110	116	117
Total assets	124	129	134
Revenue	34	24	42
Net income	5	-1	6
Dividend per share	-	-	-



3. Overview of the Transferee

Overview of the Transferee			
(1) Name	Bausch + Lomb Corporation		
(2) Address	520 Applewood Crescent, Vaughan, Ontario L4K 4B4, Canada		
(3) Representative	Brent Saunders, CEO		
(4) Date of Incorporation	August 25, 2020		
(5) Principal Business	Research, development, manufacture and sale of contact lenses, intraocular lenses and other medical devices, surgical systems and devices, lens care products, ophthalmic pharmaceuticals, and other eye health products		
(6) Capital Stock	The company has no-par value common shares and therefore does not have stated capital in the sense commonly used under Japanese corporate law.		
(7) Major Shareholder and Ownership Ratio	Bausch Health Companies Inc. (approximately 88% as of February 11, 2026)		
(8) Relationship with HOYA Corporation	Capital relationship	None	
	Personnel relationship	None	
	Business relationship	Commercial transactions exist between the two groups, including sales of Bausch + Lomb contact lenses through Eye City stores operated by the HOYA Group.	
(9) Financial Position and Operating Results for the Past Three Fiscal Years (USD billions)			
Fiscal year ended	December 2025	December 2024	December 2023
Total assets	14.0	13.5	13.4
Revenue	5.1	4.8	4.1
Operating income	0.2	0.2	0.1

4. Number of Shares to Be Transferred, Transfer Price, and Ownership Before and After the Transfer

(1) Shares Owned Before the Transfer	3,648,539 shares (ownership ratio of voting rights: 100%)
(2) Shares to Be Transferred	3,648,539 shares
(3) Shares Owned After the Transfer	0 shares (ownership ratio of voting rights: 0%)

* The transfer price will not be disclosed in light of the confidentiality obligations under the definitive agreement for the share transfer.

5. Schedule

(1) Approval Date by the CEO	October 9, 2026
(2) Definitive Agreement Signing Date	October 9, 2026
(3) Closing Date (plan)	November 2, 2026

6. Future Outlook

The transfer of the subsidiary is expected to have an immaterial impact on HOYA's consolidated financial results for the current fiscal year.

-End